Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Fostamatinib Disodium in Rheumatoid Arthritis
2010-020892-22Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fostamatinib in rheumatoid arthritis (RA), sponsored by AstraZeneca. Primary endpoint: Long-term safety and tolerability of fostamatinib. Started Jul 2010; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-020892-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020892-22.